Neumann, A.U.

patient treatment hepatitis genotype response hepatitis c study model decline therapy virus interferon kinetic ribavirin group hepatitis c virus infection baseline level hcv rna steatosi t-cell liver signi outcome result parameter treatment outcome value concentration table hcv-rna pharmacokinetic effect analysis score stage plasma dose reduction signi ficantly reduction pharmacodynamic phase hepatology peg-ifn hcv genotype 1 cirrhosis peginterferon guci score figure index ishak effectiveness production genotype 1 hcv-speci -10 sample replication university 8 model co-infected prediction brosi ficant difference caucasian il 28b week 12 ficantly virion production virion hiv replication fi rst month frequency hla-a hepatitis c patients fibrosis fi rst week african-american